Weight-loss drugs are no longer just about body weight: next-generation therapies are targeting these directions

▤ Summary

This article reviews the next generation of obesity therapies and explains how the field is moving beyond simple weight-loss endpoints. It covers multi-target incretin drugs, oral peptides, small-molecule GLP-1 agonists, and peptide conjugates, along with the challenges of balancing efficacy, safety, and long-term metabolic benefits. It also highlights the growing focus on muscle preservation, comorbidity management, and patient stratification in obesity treatment. The piece closes by emphasizing that DMPK, process development, and scalable manufacturing capabilities are becoming increasingly important as drug complexity rises.

▦ Linked Companies